The SICKLE CELL CONSORTIUM's Annual Warriors Conference is back! Our flock is flying down to Atlanta to connect with others in the sickle cell community and share more about our approach to gene therapy treatment. Opportunities like these remind us of how far we've come and all the great work that's yet to be done!
bluebird bio
Biotechnology Research
Somerville, Massachusetts 134,711 followers
Pursuing curative gene therapies to give patients and their families more bluebird days.
About us
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines
- Website
-
http://www.bluebirdbio.com
External link for bluebird bio
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Somerville, Massachusetts
- Type
- Public Company
- Founded
- 1993
- Specialties
- gene therapy, gene addition, sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy
Locations
-
Primary
455 Grand Union Blvd
Somerville, Massachusetts 02145, US
Employees at bluebird bio
Updates
-
The flock and bWILD, bluebird’s Women Influencing Leadership Development ERG, are so grateful to Kendalle Burlin O'Connell, Esq. for sharing her powerful story and her insights on the future of biotech at a fireside chat at the nest. Thank you for joining us!
CEO & President, MassBio | Chair, Bioversity | Board, The Boston Foundation | Vice Chair, American Cancer Society (ACS) Eastern New England | Board, MassBioEd Foundation
So much fun spending time at bluebird bio’s nest in Somerville, meeting with leadership and engaging with the flock responsible for delivering for patients. bluebird has such an incredible company culture that shines through the passion of everyone who works there. Love that the fireside chat was organized by your bWild ERG, which embodies your commitment to women and leadership development. Your gene therapies are changing the lives of people with #rarediseases, including most recently those with sickle cell disease and β-thalassemia. Thank you to CEO Andrew Obenshain and SVP Sarah Alspach for hosting our team. Your #patientdriven efforts are recognized and celebrated!
-
The flock was thrilled to welcome sickle cell warrior, advocate, and member of the LGBTQ+ community, Andrè Marcel Harris, to the nest for a conversation about the many aspects of Andrè's experience – his race, sexual identity, faith, and more – that intersect and overlap to shape his journey with sickle cell disease. Along with sharing his lived experiences, he also visited our lab to meet with some of the minds behind our science and participated in the flock’s Juneteenth celebrations. Warriors like Andrè inspire us to fly higher every day – thank you for joining us at the nest, Andrè!
-
bluebird bio is proud to be part of the Sickle Cell Disease Partnership and echo their sentiment – while we celebrate the successes and many contributors in the sickle cell community, we acknowledge the progress still needed and remain committed to collaborating to advance health care for all Americans living with #sicklecelldisease.
🤝In recognition of World Sickle Cell Day today, the Partnership releases a report that assesses the progress made from 2022 to 2024 on the recommendations in the National Academies’ 2020 Report on SCD. 📈"Progressing Forward: Improvements to Access to Care and Treatment for Persons with SCD” examines actions taken by Congressional and Administration officials to improve SCD policy and programs since the Partnership’s founding. 👏While the Partnership is pleased to have played a role in advancing SCD policy, it recognizes and applauds the leadership of the Partnership’s member organizations and other leaders in the SCD community. ⭐️On World Sickle Cell Day 2024, we celebrate the successes, recognize the many contributors, highlight the progress still needed, and rededicate ourselves to collaborating to advance health care for Americans with SCD.
-
Today is #Juneteenth and we're taking the time to recognize the importance of addressing the systemic inequalities that continue to affect many communities, including those living with sickle cell disease. We encourage you to take a moment to reflect on this important day in American history.
-
Warriors and advocates, like Charlotte Curtis, are working to fight misinformation and educate about the impact of #sicklecelldisease. By uplifting voices in the community who are dedicated to improving care and reducing stigma, we can help make meaningful change for people living with sickle cell disease and their families. This #WorldSickleCellDay, challenge yourself to learn more about the sickle cell community and the importance of supporting the diverse experiences of people living with sickle cell.
-
The flock had an amazing time at Foundation for Sickle Cell Disease Research’s 18th Annual Sickle Cell Disease Research & Educational Symposium. Our birds were grateful for the opportunity to attend and hear from leaders and members of the #sicklecell community. As Shanna Gillis, Manager of Patient Advocacy, shared: “My first experience at FSCDR was phenomenal! The level of authentic engagement with the community and the thought-provoking educational opportunities were unmatched. I’m looking forward to bringing all my learnings back to the nest so the flock can continue to grow and improve.”
-
Last week, members of the flock migrated to #BIO2024. Here are some of the highlights of our team flying high: ➟ We shared perspective (and some hard-won lessons!) from a decade of gene therapy leadership during a fireside chat with Andrew Dunn from Endpoints News. ➟ We facilitated a conversation among pioneers from across the healthcare ecosystem who are blazing the trail for gene therapy access in the commercial setting. ➟ We took a training hike for Luke Timmerman's Timmerman Traverse with others from across the industry who are committed to paying it forward. ➟ We heard BIO International Convention’s new CEO John F. Crowley talk about his vision for the industry and the importance of keeping patients at the heart of our work, specifically sharing the New York Times piece highlighting sickle cell disease gene therapy. ➟ We connected with advocates and other innovators who are committed to changing the world for patients and families. ➟ We celebrated how far we’ve come and all that is ahead – for bluebird, for the field of gene therapy, and for patients and their families.
-
We asked some of the newest members of the bluebird bio flock: “Why do you fly?” Hear from members of the bPACE (bluebird Patient And Community Education) and my bluebird support flocks about why they are excited to educate and empower people living with severe genetic diseases. You may see them around at upcoming community events, so be sure to say hi and ask them more about why they fly! #SickleCellAwareness
Similar pages
Browse jobs
Stock
BLUE
NASDAQ
20 minutes delay
$1.22
0.09 (7.965%)
- Open
- 1.14
- Low
- 1.13
- High
- 1.23
Data from Refinitiv
See more info on